PPT-DTG + 3TC versus DTG + TDF-FTC as Initial ART

GEMINI 1 and GEMINI 2 Week 48 Data DTG 3TC versus DTG TDFFTC as Initial ART GEMINI 1 and 2 Background Source Cahn P et al Lancet 201939314355 Study Design GEMINI 1 and 2 Background. David Geffen School of Medicine. at University of California Los Angeles. Antiretrovirals. in the Management of HIV Infection: Case-Based, Panel Discussion. From ES . Daar. , MD, at Los Angeles, Ca: April 22, 2013, IAS-USA. . Doravirine. /Lamivudine/TDF is Non-Inferior to . Efavirenz. /. Emtricitabine. /TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study. Kathleen E Squires. Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles Medical Director, Specialty . Services. Southwest CARE Center. Santa Fe, New Mexico. State-of-the-ART. . in . Antiretroviral . Management. FORMATTED: MM/DD/YY. New Orleans, Louisiana: December 15-17, 2015. Geneva, March 19 - 20 , 2015 1 | Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato, Nathan Ford Update on CADO/PADO: what are the challenges in using the current guidelines an Dovato. ). Last Updated: November 28, 2022. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Dolutegravir-Lamivudine. Photograph courtesy of . ViiV. INSTI. NRTI. 50 mg. 300 mg. Dolutegravir-Lamivudine. Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . ARV . strategies. DOR > DRV/r 1st line. (DRIVE-FORWARD W96). DTG. monotherapy. Switch PI/r-DTG (NEAT22). Switch RPV+DTG . (SWORD). Test and . Treat. D/C/F/TAF . (DIAMOND). −10% noninferiority margin for individual studies.. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. With Emergence of Comorbidities. Roger J. . Bedimo. , MD. Professor of Medicine. University of Texas Southwestern Medical Center. Dallas, TX. Learning Objectives. On completion of this presentation, learners will be able to:. ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-TDF-FTC. ROCKET-1: Design. Source: Moyle GJ, et al. . PLoS. One. 2015;10:e0116297.. Immediate switch arm. EFV-TDF-FTC. . (n = 79). Delayed switch arm . Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017. RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .